BioNTech: Q3 Earnings Insights

Shares of BioNTech BNTX rose 7% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were down 586.67% year over year to ($1.03), which missed the estimate of ($0.42).

Revenue of $78,831,000 higher by 151.99% year over year, which beat the estimate of $63,840,000.

Outlook

BioNTech hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Nov 10, 2020

Time: 08:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/jqhpczzu

Technicals

Company's 52-week high was at $115.00

Company's 52-week low was at $17.07

Price action over last quarter: Up 63.65%

Company Profile

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab, and does not yet have any commercialized medicines.